211 related articles for article (PubMed ID: 1918882)
1. Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man.
Beuers U; Fischer S; Spengler U; Paumgartner G
J Hepatol; 1991 Jul; 13(1):97-103. PubMed ID: 1918882
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats.
Purucker E; Marschall HU; Winograd R; Matern S
Biochim Biophys Acta; 2001 Apr; 1526(1):44-52. PubMed ID: 11287121
[TBL] [Abstract][Full Text] [Related]
3. Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis.
Marschall HU; Broomé U; Einarsson C; Alvelius G; Thomas HG; Matern S
J Lipid Res; 2001 May; 42(5):735-42. PubMed ID: 11352980
[TBL] [Abstract][Full Text] [Related]
4. Study of human isoursodeoxycholic acid metabolism.
Marschall HU; Roeb E; Yildiz Y; Busch N; Nguyen H; Purucker E; Thomas HG; Matern S
J Hepatol; 1997 Apr; 26(4):863-70. PubMed ID: 9126801
[TBL] [Abstract][Full Text] [Related]
5. Bile acid N-acetylglucosaminidation. In vivo and in vitro evidence for a selective conjugation reaction of 7 beta-hydroxylated bile acids in humans.
Marschall HU; Matern H; Wietholtz H; Egestad B; Matern S; Sjövall J
J Clin Invest; 1992 Jun; 89(6):1981-7. PubMed ID: 1602004
[TBL] [Abstract][Full Text] [Related]
6. delta 22-Ursodeoxycholic acid, a unique metabolite of administered ursodeoxycholic acid in rats, indicating partial beta-oxidation as a major pathway for bile acid metabolism.
Setchell KD; Yamashita H; Rodrigues CM; O'Connell NC; Kren BT; Steer CJ
Biochemistry; 1995 Apr; 34(13):4169-78. PubMed ID: 7703228
[TBL] [Abstract][Full Text] [Related]
7. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
8. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
[TBL] [Abstract][Full Text] [Related]
9. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
[TBL] [Abstract][Full Text] [Related]
10. Human liver class I alcohol dehydrogenase gammagamma isozyme: the sole cytosolic 3beta-hydroxysteroid dehydrogenase of iso bile acids.
Marschall HU; Oppermann UC; Svensson S; Nordling E; Persson B; Höög JO; Jörnvall H
Hepatology; 2000 Apr; 31(4):990-6. PubMed ID: 10733557
[TBL] [Abstract][Full Text] [Related]
11. Increase of sulfated ursodeoxycholic acid in the serum and urine of patients with chronic liver disease after ursodeoxycholic acid therapy.
Nakamura K; Yoneda M; Kimura A; Tamori K; Yokohama S; Sato Y; Kato T; Hasegawa T; Saito H; Aoshima M; Fujita M; Makino I
J Gastroenterol Hepatol; 1996 Apr; 11(4):385-90. PubMed ID: 8713707
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
[TBL] [Abstract][Full Text] [Related]
13. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man.
Rust C; Sauter GH; Oswald M; Büttner J; Kullak-Ublick GA; Paumgartner G; Beuers U
Eur J Clin Invest; 2000 Feb; 30(2):135-9. PubMed ID: 10651838
[TBL] [Abstract][Full Text] [Related]
14. Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration.
Lanzini A; De Tavonatti MG; Panarotto B; Scalia S; Mora A; Benini F; Baisini O; Lanzarotto F
Gut; 2003 Sep; 52(9):1371-5. PubMed ID: 12912872
[TBL] [Abstract][Full Text] [Related]
15. Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies.
Wang R; Liu L; Sheps JA; Forrest D; Hofmann AF; Hagey LR; Ling V
Am J Physiol Gastrointest Liver Physiol; 2013 Aug; 305(4):G286-94. PubMed ID: 23764895
[TBL] [Abstract][Full Text] [Related]
16. [Measurement of bile acid N-acetylglucosaminides in serum and urine of patients with chronic liver diseases during ursodeoxycholic acid treatment].
Kimura A; Nakamura K; Makino I
Nihon Shokakibyo Gakkai Zasshi; 1995 Mar; 92(3):224-32. PubMed ID: 7731091
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.
Jazrawi RP; de Caestecker JS; Goggin PM; Britten AJ; Joseph AE; Maxwell JD; Northfield TC
Gastroenterology; 1994 Jan; 106(1):134-42. PubMed ID: 8276175
[TBL] [Abstract][Full Text] [Related]
18. Influence of cholestasis on absorption of ursodeoxycholic acid.
Sauer P; Benz C; Rudolph G; Klöters-Plachky P; Stremmel W; Stiehl A
Dig Dis Sci; 1999 Apr; 44(4):817-22. PubMed ID: 10219843
[TBL] [Abstract][Full Text] [Related]
19. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
Lindblad A; Glaumann H; Strandvik B
Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933
[TBL] [Abstract][Full Text] [Related]
20. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.
Sinakos E; Marschall HU; Kowdley KV; Befeler A; Keach J; Lindor K
Hepatology; 2010 Jul; 52(1):197-203. PubMed ID: 20564380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
